Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 9/20 | 0.60 |
| ▸ | HTR1A | P08908 | 7/20 | 0.60 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.60 |
| ▸ | HRH1 | P35367 | 5/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4100525 | 0.98 | SLC6A2 (0.59) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL2301811 | 0.90 | SLC6A2 (0.62) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL14957027 | 0.84 | SLC6A2 (0.60) | SLC6A2HTR1ASLC6A3SLC6A4 | |
| SCHEMBL2299199 | 0.80 | PDE3B (0.41) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL649698 | 0.80 | EPHX2 (0.41) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL83377 | 0.80 | HRH1 (0.57) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL646216 | 0.80 | EPHX2 (0.41) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| Hydrochloric Acid SCHEMBL473008 | 0.79 | HRH1 (0.55) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL19527766 | 0.78 | HTR1A (0.62) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 | |
| SCHEMBL234010 | 0.77 | SLC6A2 (0.81) | SLC6A2HTR1ASLC6A3HRH1SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8592595-B2 | Preparation of (N-heterocyclyl) aryl ethers | SALTIGO GMBH (DE) | 2013-11-26 | — | — | US | claimed |
| US-20100152454-A1 | PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS | SALTIGO GMBH (DE) | 2010-06-17 | — | — | US | claimed |
| EP-2179988-A1 | Producing (N-heterocyclic) aryl ethers | Saltigo GmbH (DE) | 2010-04-28 | — | — | EP | claimed |
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-8592595-B2 | Preparation of (N-heterocyclyl) aryl ethers | SALTIGO GMBH (DE) | 2013-11-26 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | PFIZER INC. (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
| US-20100152454-A1 | PREPARATION OF (N-HETEROCYCLYL) ARYL ETHERS | SALTIGO GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| EP-2179988-A1 | Producing (N-heterocyclic) aryl ethers | Saltigo GmbH (DE) | 2010-04-28 | — | — | EP | disclosed |
| WO-2010022055-A2 | INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053165-A1 | Novel Phenyl Imidazoles and Phenyl Triazoles As Gamma-Secretase Modulators | BACE1, BACE2, PSEN1 | SLC6A2 4072/4885HTR1A 1100/4885SLC6A3 3360/4885 |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SLC6A2 475/4885HTR1A 391/4885SLC6A3 1199/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.